Diagnosis/Relapse tests
- Mutational screening using a targeted NGS panel (43 genes)
- Mutational screening by whole exome NGS
- Transcriptome profiling using RNA-seq
- Gene expression analysis by RT-PCR
- Rearrangement quantifications by RT-PCR : BCR-ABL1 (t9;22) transcripts e13a2, e14a2, e1a2, e19a2
Minimal Residual Disease (MRD) tests
- BCR-ABL rearrangement quantification by RT-PCR (p210-p190-p230)
- CloneSight-CML: MRD assesment in liquid biopsy by personalized tumor biomarkers monitoring using NGS
- ClonEv-CML: ultra-sensitive ABL1 kinase domain mutation detection using genomic DNA